RecruitingPhase 3NCT07083154
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Principal Investigator
- Yan Bi, MD, PhDNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
- Intervention
- Mazdutide(drug)
- Enrollment
- 420 target
- Eligibility
- 50-75 years · All sexes
- Timeline
- 2025 – 2029
Study locations (8)
- Department of Endocrinology, Xiangya Hospital of Central South University, Changsha, Hunan, China
- Department of Endocrinology, Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China
- Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
- Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
- Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, China
- The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
- Department of Endocrinology, Shanghai General Hospital, Shanghai, Shanghai Municipality, China
- Department of Endocrinology, Huadong Hospital Affiliated to Fudan University, Shanghai, China
Collaborators
Nanjing First Hospital, Nanjing Medical University · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Xiangya Hospital of Central South University · Huadong Hospital · Jiangsu Province Hospital of Traditional Chinese Medicine · Changzhou No.2 People's Hospital · The Second Affiliated Hospital of Dalian Medical University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07083154 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca
- RECRUITINGNCT07528781Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant VolumeGermans Trias i Pujol Hospital
- RECRUITINGPHASE2NCT07029503Swedish Cardiac And Renal Failure Study-1Karolinska Institutet
- RECRUITINGNCT07154823A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesTempus AI
- RECRUITINGNCT07328035Remission in Adults With Severe Asthma in ThailandThammasat University
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGPHASE3NCT06911502A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)Celgene
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University